| 8.98 0.42 (4.91%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.11 | 1-year : | 12.24 |
| Resists | First : | 9.51 | Second : | 10.47 |
| Pivot price | 8.73  |
|||
| Supports | First : | 7.96 | Second : | 6.62 |
| MAs | MA(5) : | 8.59 |
MA(20) : | 8.97 |
| MA(100) : | 9.42 |
MA(250) : | 6.92 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 36.3 |
D(3) : | 27.6 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 12.34 | Low : | 2.23 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FDMT ] has closed below upper band by 32.8%. Bollinger Bands are 38.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.95 - 9.99 | 9.99 - 10.04 |
| Low: | 8.45 - 8.5 | 8.5 - 8.55 |
| Close: | 8.9 - 8.98 | 8.98 - 9.05 |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Fri, 20 Mar 2026
Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies - TipRanks
Thu, 19 Mar 2026
4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st
Thu, 19 Mar 2026
4D Molecular Therapeutics (FDMT): RBC Capital Raises Price Targe - GuruFocus
Thu, 19 Mar 2026
FDMT: Chardan Capital Maintains Buy Rating with Price Target of $26.00 | FDMT Stock News - GuruFocus
Wed, 18 Mar 2026
4D Molecular Therapeutics, Inc. (FDMT) Q4 Results Surpass Forecasts for Earnings and Revenue - Bitget
Wed, 18 Mar 2026
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -104 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.101e+007 (%) |
| Held by Institutions | 3.945e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7796e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.75 |
| Profit Margin | 0 % |
| Operating Margin | -65 % |
| Return on Assets (ttm) | 538.8 % |
| Return on Equity (ttm) | -27.7 % |
| Qtrly Rev. Growth | 120000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.227e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -2.4 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 9.72e+006 |
| Forward Dividend | 9.48e+006 |
| Dividend Yield | 108241000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|